Debiopharm’s investment portfolio company Immunexpress receives the U.S. Food and Drug Administration (FDA) approval for SeptiCyte® RAPID.
SeptiCyte® RAPID is a one-hour molecular diagnostic test running on the Biocartis Idylla platform that can swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients. This is the first rapid, fully-integrated, immune response-based test to aid clinicians with sepsis diagnosis.
This follows the european launch announced a year ago.
Access the full press release here